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Abstract
Asbestos-related lung cancer accounts for 4–12% of lung cancers worldwide. We have previously identified ADAM28 as a
putative oncogene involved in asbestos-related lung adenocarcinoma (ARLC-AC). We hypothesised that similarly gene
expression profiling of asbestos-related lung squamous cell carcinomas (ARLC-SCC) may identify candidate oncogenes for
ARLC-SCC. We undertook a microarray gene expression study in 56 subjects; 26 ARLC-SCC (defined as lung asbestos body
(AB) counts .20AB/gram wet weight (gww) and 30 non-asbestos related lung squamous cell carcinoma (NARLC-SCC; no
detectable lung asbestos bodies; 0AB/gww). Microarray and bioinformatics analysis identified six candidate genes
differentially expressed between ARLC-SCC and NARLC-SCC based on statistical significance (p,0.001) and fold change (FC)
of .2-fold. Two genes MS4A1 and CARD18, were technically replicated by qRT-PCR and showed consistent directional
changes. As we also found MS4A1 to be overexpressed in ARLC-ACs, we selected this gene for biological validation in
independent test sets (one internal, and one external dataset (2 primary tumor sets)). MS4A1 RNA expression dysregulation
was validated in the external dataset but not in our internal dataset, likely due to the small sample size in the test set as
immunohistochemical (IHC) staining for MS4A1 (CD20) showed that protein expression localized predominantly to stromal
lymphocytes rather than tumor cells in ARLC-SCC. We conclude that differential expression of MS4A1 in this comparative
gene expression study of ARLC-SCC versus NARLC-SCC is a stromal signal of uncertain significance, and an example of the
rationale for tumor cell enrichment in preparation for gene expression studies where the aim is to identify markers of
particular tumor phenotypes. Finally, our study failed to identify any strong gene candidates whose expression serves as a
marker of asbestos etiology. Future research is required to determine the role of stromal lymphocyte MS4A1 dysregulation
in pulmonary SCCs caused by asbestos.
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Introduction
Despite advances in research and treatment, lung cancer
remains one of the leading causes of death globally, with five-
year survival rates as low as 15% [1]. While the majority of lung
cancers develop in smokers [2], other carcinogens including
asbestos may contribute to lung cancer development [3]. The
contribution of asbestos to lung cancer in persons exposed to both
tobacco and asbestos is difficult to quantify because of interactions
between the two agents in initiating and promoting neoplastic
changes. Apart from a history of exposure, there are no
clinicopathologic criteria distinguishing asbestos-related and
tobacco-related lung cancers [4]. Recently, we and others have
reported gene expression profiles that can potentially differentiate
between these subtypes [5].
Although lung cancer histopathologic subtypes observed in
persons with and without asbestos exposure are similar [6,7,8],
evidence is accruing that primary adenocarcinomas and squamous
cell carcinomas (SCC) of the lung arise by distinctly different
carcinogenic pathways and display different sensitivities to
targeted therapies. We recently identified ADAM28 as a candidate
oncogene in asbestos-related lung adenocarcinomas [9]. Here we
compare gene expression between asbestos-related (ARLC-SCC)
and non-asbestos related primary lung squamous cell carcinomas
(NARLC-SCC). Our aims were 1) to determine whether SCC
gene expression profiles differed between individuals with and
without evidence of prior asbestos exposure as determined by
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34943pulmonary asbestos lung fiber count, and 2) to discover and
validate candidate gene expression biomarkers of ARLC-SCC that
could be potential diagnostic markers.
Materials and Methods
Ethics Statement
This study was approved by The Prince Charles Hospital
Human Research Ethics Committee and subjects gave informed
written consent at the time of surgical resection for donation of
resected tissue for this research.
Study Population
The study population consisted of a training set of 56 cases of
primary lung SCC. Lung asbestos body count was measured in
uninvolved ‘normal’ (non-tumor) lung tissue using the bleach
digestion technique initially described by Roggli [10] and
previously outlined [11]. Urban dwellers without occupational
asbestos exposure have been found to have fewer than 20 asbestos
bodies per gram wet weight (AB/gww) using this method [12].
SCC cases were classified as ‘‘asbestos exposed’’ (n=26) if there
were $20 AB/gww in their non-tumor tissue, or ‘‘non-exposed’’
(n=30) if no asbestos bodies were found. We also used an internal
test set consisting of 3 ARLC-SCC and 9 NARLC-SCC for
biological validation. Subject demographics and tumor character-
istics are listed in Table 1.
RNA Extraction and Gene Expression Analysis
Total RNA was extracted from 20–30 mg of fresh frozen lung
tumor tissue using the TRIZol
TM reagent (Invitrogen, CA, USA),
cleaned using miRNeasy Kits (Qiagen, MD, USA) and reverse
transcribed to complementary DNA (cDNA) using a two-step
reaction. Total RNA was quantified using a Nanodrop spectro-
photometer (Thermo Scientific, DE, USA) and quality assessed
using an Agilent 2100 Bioanalyzer (Agilent Technologies, CA,
USA). Microarray experiments were performed according to
MIAME guidelines. Total RNA from single tumor samples were
hybridised to 48K Illumina HumanHT-12 V3.0 Expression
BeadChips, covering .25,000 annotated genes from the RefSeq
(Build 36.2) and Unigene databases. Arrays were scanned using an
Illumina Bead Array
TM scanner (Illumina, CA, USA) and probe
quality assessed using proprietary software (GenomeStudio, CA,
USA). Feature extraction was performed using the Gene
Expression Module of the Bead Studio software (Genome Studio,
Illumina, Hayward, CA). Data was normalised to the 75
th
percentile using GeneSpring software (Agilent Technologies).
Expression data has been deposited in the National Centre for
Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO Accession GSE23822).
Technical validation
Messenger RNA expression levels obtained from microarray
analysis in the training set (N=56), were validated against those
obtained using an independent method qRT-PCR. RNA was
reverse transcribed to cDNA using a combination of random
hexamers (100 ng/mL) and oligo (dT)15 primers (200 ng/mL)
(Promega, NSW, Australia) in a reaction with 10 mM dNTPs. Pre-
validated gene expression assays for candidate genes were
purchased from QIAGEN and assayed using SYBR green
chemistry (QIAGEN, MD, USA). Five housekeeping genes were
Table 1. Demographics for the TPCH Training and Independent Test sets.
Training Set Test Set
ARLC (.20AB/gww) NARLC (0AB/gww) P-value ARLC (.20AB/gww) NARLC (0AB/gww) P-value
N 26 30 3 9
Age (Years, Mean 6 1S D ) 65.8 (10.6) 66.4 (8.7) 0.812 67.0 (5.2) 67.4 (8.7) 0.943
Sex
Male 20 24 0.78 3 7 0.371
Female 66 02
Smoking History
Current 5 13 0.110 1 3 0.827
Former 18 16 2 5
Never 31 01
Pack years (Mean 6 1S D ) 44.4 (51.1) 51.3 (23.8) 0.528 62.7 (32.5) 66.5 (51.5) 0.908
TNM Tumor Stage
(IA and IB) 13 12 0.361 3 6 0.632
(IIA and IIB) 10 10 0 1
(IIIA and IIIB) 38 02
Self-reported asbestos exposure
Yes 7 5 0.192 2 2 0.083
No 10 20 0 0
Unknown 11 16
Missing 84 01
Asbestos Fibre Count (Mean 6 1S D ) 77.7 (103.5) 0 (0) 0.001 61.8 (48.0) 0 (0) 0.002
ARLC – Asbestos-related lung cancer; NARLC – Non-asbestos related lung cancer; AB/gww – asbestos bodies/gram wet weight; SD - standard deviation; AB – asbestos
bodies.
doi:10.1371/journal.pone.0034943.t001
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expression across individual samples was used for relative
quantification. All samples were run in triplicate on an Applied
Biosystems 7900HT Fast Machine (Applied Biosystems, Warring-
ton, United Kingdom). Genes were considered technically
replicated if the direction of differential expression for candidates
was consistent with that from array data, and the magnitude of
change was at least 1.2-fold.
Biological validation
Biological validation was performed on two independent test
sets: (1) an independent TPCH set of 12 primary SCC with
matching normal lung from our tumor bank, derived from patients
whose asbestos exposure status was determined as outlined above,
and (2) an independent external dataset of 28 lung cancer samples
of various histologies from patients whose asbestos exposure had
been assessed by occupational history and lung asbestos fiber
counts (Wikman et al [5,9]). Microarray data was kindly provided
by the authors.
Identification of a prediction panel capable of
distinguishing ARLC-SCC/NARLC-SCC
Class prediction analyses were performed in BRB Array Tools
using a random variance model and a grid of significance level
thresholds (0.01, 0.005, 0.001, and 0.0005) as tuning parameters
for classifier development (developed by Dr Richard Simon and
Amy Peng Lam, http://linus.nci.hih.gov/,brb/tool.htm). Six
different prediction models were used; (1) Compound covariate
predictor, (2) Diagonal linear discriminant analysis, (3) K-nearest
neighbour, (4) Nearest centroid, (5) Support vector machines and
(6) Bayesian compound covariate predictor. The misclassification
rate was determined using a leave-one out cross-validation
(LOOCV) procedure. With LOOCV, one sample (test) is left
out and a classifier developed on the remaining samples. This
process is repeated until all samples have been omitted once. A
permutation P-value for the cross-validated misclassification rate
was computed by repeating the cross validation procedure for
1000 permutations of the class label.
Immunohistochemistry
Immunohistochemical staining was performed using a mono-
clonal murine anti-human B cell CD20cyIG2akappa antibody
targeted to human MS4A1 (Dako, Denmark, Catalogue Number
M0755). Briefly, 4 um sections of formalin-fixed paraffin-embed-
ded tissue were cut onto Menzel Superfrost Plus slides and air
dried overnight at room temperature. Sections were dewaxed and
rehydrated through a series of xylol and ethanol rinses using a
Sakura DRS autostainer. Heat-activated antigen retrieval was
performed using the Dako antigen retrieval solution (pH 6.0) and
a Biocare Medical Decloaking chamber. The monoclonal primary
MS4A1 antibody was applied at a dilution of 1:70 and sections
counterstained using Mayer’s haematoxylin.
Statistical Analysis
Statistical analyses for microarray experiments were performed
using BRB ArrayTools Version 3.8; developed by Dr Richard
Simon and Amy Peng Lam, http://linus.nci.hih.gov/,brb/tool.
htm. Candidate genes were selected on (a) statistical significance of
expression (P,0.001) and (b) magnitude of expression change (fold
change .2.0). Selection of genes at P,0.001 (by Student t-test)
allowed control of the false discovery rate, limiting the likelihood of
selecting false positives. Group comparisons, correlations and
associations were performed using x
2 tests and two-tailed t-tests
where appropriate using SPSS statistical software (Version 17,
SPSS Inc Chicago, IL, USA). Two tailed p-values less than 0.05
were considered statistically significant.
Results
Summary distributions for age, gender, smoking history and
tumor stage for the fifty-six subjects in the training set and twelve
test set subjects are shown in Table 1. There were no statistically
significant differences in age, gender, smoking history or tumor
stage between ARLC-SCC and NARLC-SCC in either the
training or test sets (Table 1).
Class comparison to identify ARLC-SCC associated
oncogenes and tumour suppressor genes
Based on a univariate parametric t-test, supervised analysis of a
total of 8,239 probes in the 56 lung cancers in the training set
identified 484 probes differentially expressed between ARLC-SCC
(n=26) and NARLC-SCC (n=30) (P,0.05) with 412 expected by
chance. Supervised hierarchical clustering using centred correla-
tion with average linkage showed that these 484 probes were able
to distinguish between ARLC-SCC and NARLC-SCC (Figure 1).
To identify individual gene expression markers of ARLC-SCC,
we prioritised the 484 genes on the basis of p-value and magnitude
of change. Six of these genes satisfied threshold criteria consisting
of P value,0.001 and .2 fold mean differential expression
between groups in microarray analysis (Table 2, Figure 2A). In the
same samples, only two genes were independently confirmed as
differentially expressed in the same direction as the microarray
analysis by the independent method of qRT-PCR: caspase
recruitment domain family, member 18 (CARD18) and mem-
brane-spanning 4-domains, subfamily A, member 1 (MS4A1)
(Figure 2B). For both genes the magnitude of higher expression in
ARLC compared with NARLC by qRT-PCR was relatively small
(,2.5 fold; Table S1).
In our independent test set of 12 primary lung SCC cases
MS4A1 expression was only 1.7 fold higher in tumor tissue (lung
SCC) compared with autologous normal lung, whereas CARD18
was 73 fold higher in tumor (ratio of lung cancer versus normal
lung mean; Table S1). This large change is likely due to the small
sample size and may not necessarily reflect the normal changes
seen in normal lung and lung cancer.
To determine whether the differential expression of these two
genes was specific to asbestos related SCC, we interrogated our
previous microarray analysis of asbestos related lung adenocarci-
noma (ARLC-AC; GSE20875). MS4A1, but not CARD18, was up
regulated in ARLC-AC compared with non ARLC-AC, but the
magnitude of fold change was small (FC 1.2, P=0.021; Table S2).
In the external independent validation set of Wikman and co-
workers, MS4A1 was represented by two probes on the Affymetrix
HG-U133A microarray chip, used to study gene expression in
lung cancers from patients with and without asbestos exposure [5].
Both probes were up-regulated in asbestos related tumours (Probe
1 FC=1.59; Probe 2 FC=1.38, Figure 2B; Table S2) but the
magnitude of up regulation was again small. CARD18 was not
represented on the Affymetrix HG-U133A chip.
Because MS4A1 encodes the CD20 B lymphocyte marker, the
origin of its up regulation in ARLC-SCC which comprises primary
tumor cells as well as stroma was explored using immunohisto-
chemistry to determine if deregulation was due to stromal
lymphocytes rather than lung tumor cells. Fifty-two cases with
formalin-fixed paraffin-embedded tumor tissue available for
immunohistochemistry were studied with anti-CD20, and no
staining was observed in tumor cells. As predicted, the source of
Expression Profiling of Asbestos-Related SCC
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Stromal lymphocytes are often found within the connective tissue
septa between nests of tumour cells, and are sometimes
accompanied by plasma cells. However CD20 positive tumor
infiltrating lymphocytes (TILs) were also observed in seven tumors
(six asbestos related, one non-asbestos related). TILs are
lymphocytes actually within tumor cell nests, seen in sections as
being between or on top of tumor cells. Representative CD20
stains are shown in Figure 3.
Identification of gene expression profiles to classify
ARLC-SCC from NARLC-SCC
Next in order to identify a gene expression classifier capable of
distinguishing ARLC-SCC from NARLC-SCC we performed
class prediction analysis using six standard models; (1) Compound
Covariate, (2) Diagonal Discriminant Analysis, (3) K-nearest
neighbor (K=1,3), (4) Nearest Centroid, (5) Support Vector
Machines and (6) Bayesian Compound covariate models. None of
these models were able to correctly classify more than 57% of
SCCs. The best predictor, K-nearest neighbor (k=1) misclassified
fifteen of twenty-six ARLC-SCC tumors and demonstrated poor
test characteristics: sensitivity 42.3%, specificity 70%, positive
predictive value 55%, negative predictive value 58.3% (permuta-
tion p-value=0.296 based on 1000 permutations of the class
label).
Discussion
The exact contribution of asbestos to lung cancer burden in
modern times is difficult to ascertain with certainty. While asbestos
has been shown to chemically and physically interact with DNA,
its precise carcinogenic mechanisms in lung and pleura remain
unknown. In an attempt to better understand the molecular
mechanisms of asbestos related carcinogenicity in squamous cell
carcinoma of the lung, we examined the gene expression profiles of
56 SCC; 26 ARLC-SCC ($20AB/gww) and 30 NARLC-SCC (0
AB/gww) using Illumina gene expression microarrays.
To date, only one study has investigated gene expression profile
differences between primary lung cancers from asbestos-exposed
individuals versus those without evidence of asbestos exposure.
Wikman et al. identified a 47-gene signature capable of
distinguishing ARLC/NARLC classes [13], demonstrating the
potential to use gene expression profiling to identify asbestos-
related tumor biomarkers. We also previously found evidence that
gene expression profiles differ between asbestos-related lung
adenocarcinoma (ARLC-AC) and adenocarcinoma unrelated to
asbestos (NARLC-AC) [9]. Based on these two studies we
expected that gene expression profiles would differ between
squamous cell carcinomas related and unrelated to asbestos
(ARLC-SCC and NARLC-SCC respectively). Our results do not
support this hypothesis in that Illumina microarray gene
expression profiles were unable to differentiate SCCs according
to lung asbestos body counts with enough sensitivity or specificity
to be useful as a diagnostic test.
Despite the fact that the Illumina platform has been shown to be
highly correlated with Taqman technology [14], only two of the
top six differentially expressed genes selected on p-value and
magnitude of expression difference (MS4A1 and CARD18) were
verified by the independent method of qRT-PCR. The limited
dynamic range and lower sensitivity of microarrays for gene
expression may account for the different results obtained with the
more sensitive qRT-PCR method. Secondly, different primer
positions relative to the microarray probe locations could reduce
consistency between the two methods e.g. if qRT-PCR primers are
located far from the microarray probe, correlation may be weaker
[15]. We used validated primers from QIAGEN for qRT-PCR
and found that they were located close to the microarray probe for
3/6 genes. Although we tried to select primers targeted to the
specific transcript the array probe was designed to amplify,
undocumented splice variants in some genes could allow
preferential amplification of specific transcripts. Several groups
have investigated the relationship between microarray and qRT-
PCR data reporting higher correlations for up-regulated genes,
genes with high magnitudes of change, and genes with lower p-
Figure 1. Heat map depicting the genomic profiles of asbestos-related (yellow) and non-asbestos related (black) lung squamous
cell carcinomas. Genes were selected on the basis of statistical significance (P,0.05). Genes are represented on the Y axis and tumor samples
represented on the X axis. Blue areas represent genes that are under-expressed in the tumor sample while red areas represent genes over expressed
in the tumor sample.
doi:10.1371/journal.pone.0034943.g001
Table 2. Microarray identified differentially expressed genes between ARLC and NARLC in the training set.
Illumina
Probe ID
Genbank
Accession Gene Symbol Gene Description Fold Change Chromosome Map P-value
4280288 NM_021571.2 CARD18 caspase recruitment domain family,
member 18
2.894 11 11q21-q22 2.64E-05
2710615 NM_015600.3 ABHD12 abhydrolase domain containing 12 2.576 20 20p11.21 3.19E-04
7050523 NM_006595.2 API5 apoptosis inhibitor 5 3.204 11 11p12 3.86E-04
4120669 NM_001080500.1 LOC402117 von Willebrand factor C domain-
containing protein 2-like
22.664 2 2q34-q35 5.52E-04
1940010 NM_152866.2 MS4A1 membrane-spanning 4-domains,
subfamily A, member 1
2.371 11 11q12.2 7.42E-04
4180609 NM_001012419.1 ANKRD20A3 ankyrin repeat domain 20 family,
member A3
22.400 9 9q12 7.68E-04
The top 6 genes were selected on the basis of high magnitude (.2.0 fold) and statistical significance (p,0.001). These candidates were then biologically validated in
independent test sets and technically replicated using an independent method, qRT-PCR.
doi:10.1371/journal.pone.0034943.t002
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correlations for genes exhibiting small expression differences (,2-
fold) [17,18]. However, the candidate genes we studied demon-
strated relatively high differential expression (.2-fold), making it
unlikely that magnitude of expression difference would account for
inability to technically validate.
Despite class comparison identifying 484 probes capable of
separating ARLC-SCC and NARLC-SCC, there were only two
validated genes emerging as potential candidate markers of
ARLC-SCC from supervised class comparison analysis. Despite
selecting candidates at stringent P-values (P=0.001) and high
magnitude (.2-fold change), probes contained within the original
484-probe profile exhibited very high false discovery rates.
Nonetheless, the study was sufficiently powered to detect
differences between the two groups. This may reflect lack of
biological differences between ARLC-SCC and NARLC-SCC.
Not surprisingly then, class prediction analysis failed to identify
a primary tumor signature capable of distinguishing ARLC-SCC
and NARLC-SCC with adequate sensitivity and specificity to be
useful as a clinical test. This also suggests biological similarity
between ARLC and NARLC.
The two qRT-PCR validated candidate genes from microarray
class comparison, MS4A1 and CARD18 were identified as up
regulated in ARLC-SCC compared with NARLC-SCC. Although
Figure 2. Gene expression differences for the top 6 candidates as measured by microarray and qRT-PCR in the training and test
sets. A. Heat map depicting the genomic profiles of asbestos-related (green) and non-asbestos related (orange) lung squamous cell carcinomas. Genes
were selected on the basis of statistical significance (P,0.001) and magnitude of gene expression change (.2.0-fold). Genes are represented on the Y
axis and tumor samples represented on the X axis. Blue areas represent genes that are under-expressed in the tumor sample while red areas
represent genes over expressed in the tumor sample. B. Bar graph depicting gene expression changes in TPCH Microarray data, TPCH qRT-PCR (Training
and Testing sets) and Wikman Microarray Data. Fold changes are the mean of ARLC-SCC/mean NARLC-SCC group. TPCH – The Prince Charles Hospital.
doi:10.1371/journal.pone.0034943.g002
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squamous cell lung cancers compared with that of autologous non-
tumor lung tissue, the magnitude of differential expression
between ARLC-SCC and NARLC-SCC was modest. This gene
was not differentially expressed in lung adenocarcinomas accord-
ing to asbestos exposure. Taken together, these observations are
consistent with high expression of CARD18 in SCC, but suggest
that CARD18 is not a good discriminatory marker for ARLC-SCC
versus NARLC-SCC.
The protein product of CARD18, ICEBERG, is a 90 amino acid
protein encoded on 11q22.3, and a member of the death domain
superfamily whose members form protein-protein interactions
(homodynes or heterodimers) to function as adaptors in signaling
pathways or to recruit other proteins into signaling complexes.
ICEBERG is a CARD (capsize activation and recruitment
domain) only protein, induced by pro-inflammatory stimuli. It
binds to the prodomain of caspase-1 preventing its association with
RIP2 and inhibiting synthesis of interleukin-1-beta. While some
CARD only proteins activate the nuclear transcription factor NF-
kB, there is no evidence that ICEBERG is involved in its
activation [19], so the significance of its elevated expression in lung
SCC and particularly asbestos related SCC is unknown. As our
tumor samples were not micro-dissected or otherwise enriched for
tumor content, it is unknown whether the CARD18 signal in
squamous cell carcinoma originates from tumor cells themselves or
from stromal elements.
The other gene with verified differential expression between
ARLC-SCC and NARLC-SCC was MS4A1. Its level of expression
was somewhat higher in SCC tumor tissue compared with non-
malignant autologous lung, and in ARLC (both SCC and AC)
compared with NARLC. Although of small magnitude, the
differential expression of this gene was consistent and was
associated with ARLC of both major histopathologic subtypes.
MS4A1 expression has also been shown to be inducible by
crocidolite in in vitro model systems of asbestos exposure.
The MS4A1 gene located on 11q12 encodes a member of the
membrane-spanning 4-domains, subfamily A, B lymphocyte
antigen CD20, which plays a role in differentiation of B
lymphocytes into plasma cells [20]. Inhibitory monoclonal
antibodies to CD20 such as rituximab are therapeutic in several
hematologic malignancies and immunologically driven inflamma-
tory diseases including rheumatoid arthritis [21]. Apart from its
classical expression in B-lineage haemopoetic cells, CD20 has been
associated with aggressive clinical behavior in a microarray gene
expression study of melanoma [22]. Intriguingly tumorigenic
melanoma cells were found to be enriched within a CD20+
fraction, suggesting that melanoma cancer stem cells are
pluripotent and express CD20 [23]. If the CD20 signal in ARLC
Figure 3. Representative CD20 immunohistochemistry in non-small cell lung cancer at 1006magnification. a and b. Tumor cells fail to
stain; positivity seen only in stromal B-lymphocytes. c and d. Tumor cells again negative; CD20-positive B-cells infiltrating tumor nests and stroma. e.
Positive control (reactive lymph node). f. Negative control (lymph node without primary antibody).
doi:10.1371/journal.pone.0034943.g003
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possibility of targeting these specifically with existing monoclonal
antibody therapeutics arises. To explore this possibility and
determine the cellular source of CD20 within lung cancers, we
studied the localization of CD20 protein in fifty-two SCCs using
immunohistochemistry with anti-CD20 antibodies. The CD20
signal appeared to be primarily of lymphocytic rather than tumor
cell origin, with the majority of the signal arising from stromal
lymphocytes. A small proportion of tumors also showed CD20
staining in tumor infiltrating lymphocytes (TILs). Nevertheless, the
absence of tumor cell CD20 staining in all fifty-two cases and
positive stromal lymphocyte immunostaining in most tumors
indicates that the CD20 expression signal observed in microarray
and qRT-PCR almost certainly originates from lymphocytes
located mainly within stroma.
In our microarray expression analysis of macro-dissected
tumors, the finding of a gene of interest predominantly expressed
in stromal rather than tumor cells raises a significant issue
concerning the method of tumor sample preparation, and
indicates the possibility of a stromal effect from asbestos. The
effect of the proportion of stromal content on results of tumor gene
expression profiling has been reported. In some studies the method
of dissection (macro versus micro) was found to have only minor
effects on the tumor gene expression profile [24,25]. Conversely,
Klee and colleagues showed that laser micro dissection (LCM) was
capable of identifying differentially expressed genes not identified
using bulk dissection methods [26] suggesting that LCM provides
greater sensitivity for detection of differentially expressed markers.
While debate continues, LCM based sample preparation would
seem to be preferred where the goal is to identify tumor specific
markers as it provides tumor cell enrichment.
There is increasing recognition that cancer cells rely on the
surrounding microenvironment to driver the cancer phenotype
favouring survival, growth and spread [27]. Tumor behaviours
such as progression and prognosis are dependent on cellular
interactions between tumor cells and stromal elements including
immune cells and cells of mesenchymal origin [27]. For example
‘reactive stroma’ containing fibroblasts and myofibroblasts char-
acterise numerous invasive cancers including lung cancer with bi-
directional cross-talk between tumor cells and stromal elements
important for fibroblast differentiation [27]. In particular myofi-
broblasts and fibroblasts provide an important source of
extracellular matrix proteins which are important for development
of the extracellular matrix in tumor stroma [27]. Inclusion of
stromal elements in study samples is therefore important, enabling
discovery of potentially important information about the tumor
microenvironment. Thus, the finding of a gene expressed
predominantly in the stroma alludes to the possibility of a
tumor-stroma interaction generated by asbestos.
A potential limitation of this study is the method of sample
preparation used. As the primary aims were to identify gene
expression profile differences and differentially expressed genes
with potential diagnostic or therapeutic relevance, if redesigning
this study we would use microdissected samples. Our results are of
interest in highlighting the critical importance of methodology to
interpretation of results in high dimensional gene expression
studies, and of the need for verification with independent methods.
Future gene expression studies should concentrate on determining
their study aims and relevant methodology before embarking on
microarray profiling experiments to ensure their question is
answered adequately.
In summary, in this study we identified gene expression profile
differences between ARLC-SCC and NARLC-SCC, but failed to
verify the differential expression of individual genes that were
highly significant in microarray analysis using the independent
method of qRT-PCR. We found CARD18, encoding the capsize 1
interacting protein ICEBERG, specifically up-regulated but in
small magnitude in ARLC-SCC (but not ARLC-AC). We also
found MS4A1 encoding the B-lymphocyte marker CD20, to be up-
regulated in ARLC (both SCC and AC), and traced this signal to
stromal lymphocytes rather than tumor cells.
The finding of a candidate gene primarily expressed in stromal
lymphocytes rather than tumor cells suggests that study design and
sample preparation methods must be considered when interpret-
ing microarray study results. This study also calls for more
research to determine the possible role of MS4A1 in ARLC given it
was found in both AC and SCC. For our purposes, tumor cell
enrichment by microdissection may have avoided the emergence
of dominant signals from stromal elements, as illustrated by
identification of MS4A1 as a gene of interest. Conversely, it also
demonstrates the advantage of using macrodissection by allowing
an appreciation of the contribution of stroma which is known to be
important in cancer development [27]. On the other hand,
microdisection for gene expression studies enables more precise
identification of gene dysregulation in lung cancer cells only;
similarly for clonal cell lines. Our findings however suggest both of
these study designs are helpful and indeed complementary, and
stress the need for independent validation and replication Future
studies attempting to identify expression markers of asbestos
related SCC should carefully consider this and other design
aspects to achieve their specific goals.
Supporting Information
Table S1 Gene Expression values of candidate genes in
TPCH Microarray data, TPCH qRT-PCR (Training and
Test Sets) and Wikman Microarray Data.Fold Changes are
mean ARLC/mean NARLC. Where there was multiple probes
for the gene, the mean expression across all array probes was used.
*Average fold change of all probes used.
(XLSX)
Table S2 Gene expression values for the Wikman and
Wright Lung Adenocarcinoma Microarray Data. Fold
changes for each probe on the array are tabulated. Fold changes
for each probe on the array are tabulated.
(XLSX)
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